Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study

European Journal of Heart Failure

Volumn 18, Issue 7, 2016, Pages 830-839

  Biegus, Jan ^a,b   Hillege, Hans L ^c   Postmus, Douwe ^c   Valente, Mattia A E ^c   Bloomfield, Daniel M ^d   Cleland, John G F ^e   Cotter, Gad ^f   Davison, Beth A ^f   Dittrich, Howard C ^g   Fiuzat, Mona ^h   Givertz, Michael M ⁱ   Massie, Barry M ^j   Metra, Marco ^k   Teerlink, John R ^j   Voors, Adriaan A ^c   O'Connor, Christopher M ^h   Ponikowski, Piotr ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF HULL   (United Kingdom)

^f Momentum Research Inc   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

Acute heart failure; Liver dysfunction; Liver function tests; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; FUROSEMIDE; HEMOGLOBIN; INOTROPIC AGENT; PLACEBO; ROLOFYLLINE; VASODILATOR AGENT;

ABNORMAL LABORATORY RESULT; ACUTE HEART FAILURE; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84979035744     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.532     Document Type: Article

References (21)

1. Gheorghiade M, Pang PS. Acute Heart Failure Syndromes. J Am Coll Cardiol 2009;53:557–573.
2. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196–206.
3. Peacock WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AHB. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117–2126.
4. O'Connor CM, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, Cleland J, Bloomfield D, Dittrich HC, DeLucca P, Givertz MM, Mansoor G, Ponikowski P, Teerlink JR, Voors AA, Massie BM, Cotter G, Metra M. Impact of serial troponin release on outcomes in patients with acute heart failure: Analysis from the protect pilot study. Circ Hear Fail 2011;4:724–732.
5. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004;94:957–960.
6. Allen LA, Felker GM, Pocock S, McMurray JJV, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170–177.
7. van Deursen VM, Damman K, Hillege HL, van Beek AP, Veldhuisen DJ van, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16:84–90.
8. Shinagawa H, Inomata T, Koitabashi T, Nakano H, Takeuchi I, Naruke T, Ohsaka T, Nishii M, Takehana H, Izumi T. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J 2008;72:364–369.
9. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 2012;14:302–311.
10. Deursen VM van, Edwards C, Cotter G, Davison BA, Damman K, Teerlink JR, Metra M, Felker GM, Ponikowski P, Unemori E, Severin T, Voors AA. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. J Card Fail 2014;20:407–413.
11. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect. J Card Fail 2010;16:25–35.
12. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419–1428.
13. Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, Ponikowski P, Metra M, Teerlink JR, Cleland JG, Dittrich HC, O'Connor CM, Cotter G, Voors AA. Renal function trajectories and clinical outcomes in acute heart failure. Circ Heart Fail 2014;7:59–67.
14. Biegus J, Zymliński R, Sokolski M, Nawrocka S, Siwołowski P, Szachniewicz J, Jankowska EA, Banasiak W, Ponikowski P. Liver function tests in patients with acute heart failure. Pol Arch Med Wewnętrznej 2012;122:471–479.
15. Nikolaou M, Parissis J, Yilmaz MB, Seronde M-F, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre P-F, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013;34:742–749.
16. Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF, Califf RM, Gheorghiade M. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008;1:25–33.
17. Harjola V-P, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12:239–248.
18. Couteur DG Le, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, Seibel MJ, Waite LM, Cumming RG. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol Ser A Biol Sci Med Sci 2010;65A:712–717.
19. Androne ASA-S, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226–229.
20. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008;155:883–889.
21. Liu M, Chan CP, Yan BP, Zhang Q, Lam YY, Li RJ, Sanderson JE, Coats AJ, Sun JP, Yip GWK, Yu CM. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2012;14:39–44.